1. Evaluation of liver fibrosis using hepatic extracellular volume fraction by contrast-enhanced computed tomography before and after direct-acting antiviral therapy in patients with chronic hepatitis C infection: comparison with serological liver fibrosis markers
   Akihiko Kanki et al, 2021, The British Journal of Radiology CrossRef
2. The 90‐Day Survival Threshold: A Pivotal Determinant of Long‐Term Prognosis in HBV‐ACLF Patients – Insights from a Prospective Longitudinal Cohort Study
   Lanlan Xiao et al, 2024, Advanced Science CrossRef
3. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
   Pei-Yuan Su et al, 2021, Journal of Clinical Medicine CrossRef
4. Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors
   Patrizia Carrieri et al, 2022, JHEP Reports CrossRef
5. The changing non-invasive fibrosis index value in patients with hepatitis C treated with direct-acting antiviral agents
   Derya ARI et al, 2022, Akademik Gastroenteroloji Dergisi CrossRef